

individual being readied for peripheral stem cell pheresis. Control testing is not necessary on days when patient testing is not performed.

There must be written guidelines defining objective criteria for acceptable performance of control material and records of the evaluation of the actual performance.

If the laboratory performs quantitative test procedures for which control materials are not commercially available, there are written procedures for an alternative mechanism to detect immediate errors and monitor test system performance over time. The performance of alternative control procedures must be recorded. "Performance" includes elements of accuracy, precision, and clinical discriminating power. Examples of alternative procedures may include split sample testing with another method or with another laboratory, the testing of previously tested patient specimens in duplicate, testing of patient specimens in duplicate, or other defined processes approved by the laboratory director.

Evidence of Compliance:

- ✓ Records of QC results

REFERENCES

- 1) Department of Health and Human Services, Centers for Medicare and Medicaid Services. Clinical laboratory improvement amendments of 1988; final rule. *Fed Register*. 1992(Feb 28):7146 [42CFR493.1256]

FLO.23925 Control Range Establishment or Verification Phase II



The laboratory establishes or verifies an acceptable control range for each lot of control material.

NOTE: For unassayed control materials, the laboratory must establish an acceptable control range by repetitive analysis in runs that include previously tested control material. For assayed control materials, the laboratory must verify control ranges supplied by the manufacturer.

Control values supplied by the manufacturer may be used without verification for qualitative (eg, positive or negative) testing.

Evidence of Compliance:

- ✓ Records for control range establishment or verification of each lot

REFERENCES

- 1) Clinical and Laboratory Standards Institute (CLSI). *Evaluation of Precision of Quantitative Measurement Procedures. Approved Guideline*. 3rd ed. CLSI document EP05-A3. Clinical and Laboratory Standards Institute, Wayne, PA; 2014.
- 2) Clinical and Laboratory Standards Institute. *Statistical Quality Control for Quantitative Measurement Procedures, Principles and Definitions*. 4th ed. CLSI guideline C24. Clinical and Laboratory Standards Institute, Wayne, PA, 2016.

FLO.24230 QC Corrective Action Phase II

The laboratory performs and records corrective action when control results exceed defined acceptability limits.

NOTE: The actions taken must be consistent with the laboratory's quality control program (GEN.30000). Patient test results obtained in an analytically unacceptable test run or since the last acceptable test run must be re-evaluated to determine if there is a significant clinical difference in patient/client results. Re-evaluation may or may not include re-testing patient samples, depending on the circumstances.

Even if patient samples are no longer available, test results can be re-evaluated to search for evidence of an out-of-control condition that might have affected patient results. For example, evaluation could include comparison of patient means for the run in question to historical patient means, and/or review of selected patient results against previous results to see if there are consistent biases (all results higher or lower currently than previously) for the test(s) in question.

Evidence of Compliance:

- ✓ Records of corrective action for unacceptable control results

REFERENCES

- 1) Department of Health and Human Services, Centers for Medicare and Medicaid Services. Clinical laboratory improvement amendments of 1988; final rule. *Fed Register*. 2003(Oct 1):1046 [42CFR493.1282(b)(2)]

FLO.24250 QC Handling Phase II

The laboratory tests control specimens in the same manner and by the same personnel as patient samples.

NOTE: Personnel who routinely perform patient testing must analyze QC specimens; however, this does not imply that each operator must perform QC daily. Personnel must participate in QC on a regular basis. To the extent possible, all steps of the testing procedure must be controlled.

Evidence of Compliance:

- ✓ Records reflecting that QC is run by the same personnel performing patient testing

REFERENCES

- 1) Department of Health and Human Services, Centers for Medicare and Medicaid Services. Clinical laboratory improvement amendments of 1988; final rule. *Fed Register*. 2003(Jan 24):7166 [42CFR493.1256(d)(8)]

FLO.24300 QC Confirmation of Acceptability Phase II

Personnel review control results for acceptability before reporting patient/client results.

Evidence of Compliance:

- ✓ Records of control result approval

REFERENCES

- 1) Department of Health and Human Services, Centers for Medicare and Medicaid Services. Clinical laboratory improvement amendments of 1988; final rule. *Fed Register*. 2003(Jan 24):7166 [42CFR493.1256(f)]

FLO.24475 Monthly QC Review Phase II

The laboratory director or designee reviews and assesses quality control data at least monthly.

NOTE: The reviewer must record follow-up for outliers, trends, or omissions that were not previously addressed.

The QC data for tests performed less frequently than once per month may be reviewed when the tests are performed.

Evidence of Compliance:

- ✓ Records of QC review **AND**
- ✓ Records of corrective action taken when acceptability criteria are not met

INSTRUMENTS AND EQUIPMENT

FLOW CYTOMETERS

The checklist requirements in this section should be used in conjunction with the requirements in the All Common Checklist relating to instruments and equipment.